By Gwendolyn Wu
Published September 22, 2026
Amgen, the biotechnology giant, has announced a significant clinical victory for its experimental drug, dazodalibep, marking a potential turning point in the treatment of Sjögren’s syndrome—a chronic and debilitating autoimmune disorder that has historically eluded effective pharmacological intervention. The results, stemming from the first of two pivotal late-stage trials, offer a glimmer of hope for the millions of patients worldwide suffering from the systemic condition, which is characterized by the body’s immune system attacking its own moisture-producing glands.
The drug, a key asset inherited through Amgen’s multi-billion dollar acquisition of Horizon Therapeutics, has now cleared its initial hurdle in a competitive landscape where industry heavyweights are racing to secure the first approved therapy for the condition.
The Clinical Challenge: Why Sjögren’s Remains a "Tricky Target"
Sjögren’s syndrome is frequently described by clinicians as one of the most difficult autoimmune diseases to treat. Unlike more common conditions that may be managed with existing anti-inflammatory biologics, Sjögren’s presents a complex, multi-faceted pathology. The disease involves the immune system errantly attacking moisture-producing glands, leading to chronic, severe dry eyes and mouth. However, the systemic reach of the condition goes far beyond these symptoms; patients often endure profound fatigue, joint pain, and widespread organ inflammation.
Crucially, those living with the disorder face a significantly elevated risk of developing lymphoma, a form of blood cancer. Despite the severity of these health outcomes, there are currently no regulatory-approved treatments capable of altering the fundamental course of the disease. Most standard care is limited to palliative measures, such as artificial tears and saliva substitutes, which fail to address the underlying immunological dysfunction.
Mechanism of Action: The CD40-CD40L Pathway
Dazodalibep represents a sophisticated approach to modulating the immune system. The drug functions by interfering with a critical communication channel between immune cells: the CD40-CD40L signaling pathway.
In a healthy immune response, this pathway is essential for the activation of B cells and the subsequent production of antibodies. In the context of Sjögren’s, this pathway becomes hyperactive, leading to the formation of tissue-damaging autoantibodies. By blocking this interaction, dazodalibep aims to "quiet" the hyperactive immune response, thereby preventing the persistent inflammation that drives the disease.
The drug’s potential was initially validated in a Phase 2 trial, where participants demonstrated a statistically significant reduction in systemic disease activity and a noticeable improvement in overall symptoms. These earlier successes provided the foundation for the current Phase 3 program, which is designed to provide the robust evidence required for regulatory submission.
A Tortuous Path to Amgen: The Chronology of Development
The journey of dazodalibep from discovery to late-stage clinical trials is a testament to the consolidation and evolution of the modern biopharmaceutical industry.
- Initial Discovery: The molecule was first identified and developed by researchers at AstraZeneca, who saw the potential for targeting the CD40-CD40L pathway.
- The Viela Bio Spinout: To better focus on the development of rare disease assets, AstraZeneca spun the drug out into a specialized startup, Viela Bio.
- Horizon Therapeutics Acquisition: In 2021, Horizon Therapeutics recognized the value of Viela’s pipeline, particularly the potential for dazodalibep in autoimmune disorders, and moved to acquire the company.
- The Amgen Mega-Deal: In a landmark 2023 transaction, Amgen completed its massive $27.8 billion acquisition of Horizon Therapeutics. This move allowed Amgen to fold dazodalibep into its extensive portfolio of inflammatory and autoimmune medicines, effectively making it one of the most closely watched assets in its R&D engine.
The Path Forward: Supporting Data and Trial Design
The data released this week originates from the first of two pivotal Phase 3 studies. While Amgen has opted not to disclose the granular, line-by-line findings ahead of a future presentation at a medical conference, the topline results were sufficient to meet the primary endpoints of the study.
"These topline results provide further support for dazodalibep as an emerging treatment for improving systemic disease activity and represent an important advance for the field," said Ghaith Noaiseh, the study’s lead investigator and an immunology professor at the University of Kansas Medical Center.
However, the path to the market remains complex. Amgen is currently conducting a second pivotal trial specifically targeting patients who exhibit a "high symptom burden." Data from this second study is expected to be released in the fourth quarter of 2026. Experts note that because the two trials involve distinct patient populations, regulatory success will likely depend on the company’s ability to demonstrate efficacy across both groups.
Competitive Implications: The Race to the Finish Line
Amgen is not alone in the race to bring the first therapy to market. The competitive landscape for Sjögren’s syndrome treatments is rapidly heating up, with several major players vying for the lead position.
The Novartis Factor
Novartis is perhaps the most immediate threat to Amgen’s market entry. The company’s experimental therapy, ianalumab, has shown strong promise in clinical settings and is currently being scrutinized by regulatory agencies. There is industry speculation that ianalumab could receive regulatory clearance as early as this quarter, potentially setting a benchmark for efficacy and safety that future entrants—including Amgen—will be forced to match.
The BMS Pipeline
Bristol Myers Squibb (BMS) is also making a concerted effort to expand the reach of its existing portfolio. The company is currently testing Sotyktu, a marketed treatment for psoriasis, in patients with Sjögren’s. While the scientific community is awaiting the results of this trial, market analysts have expressed varying levels of optimism regarding its success.
Analyst Perspectives
David Risinger, an analyst at Leerink Partners, noted that the specific data points Amgen eventually unveils will be vital for determining how the drug will be positioned against Novartis’s ianalumab. Regarding the broader competitive landscape, Risinger suggested that his team and other industry observers maintain "very low expectations" for the potential of the Bristol Myers Squibb study, effectively narrowing the contest to a head-to-head race between Amgen and Novartis.
Matt Phipps, an analyst at William Blair, expressed a more nuanced view. In a recent note to clients, Phipps stated he was "encouraged" by the news of the successful trial, noting that his team had previously viewed the dazodalibep program as "relatively high risk." However, he cautioned investors that despite this win, the necessity of a second victory in the upcoming Phase 3 trial remains the primary hurdle for the drug’s ultimate commercialization.
Strategic Implications for Amgen
For Amgen, a successful launch of dazodalibep would be a significant validation of its acquisition strategy. By integrating Horizon Therapeutics, Amgen not only gained established revenue streams but also acquired a pipeline of highly specialized assets that align with its core strengths in immunology and biotechnology.
If dazodalibep receives approval, it will likely serve as a cornerstone for Amgen’s efforts to expand its footprint in the autoimmune market. Given the lack of existing disease-modifying therapies for Sjögren’s, the potential market for a safe and effective drug is substantial.
As the fourth quarter approaches, all eyes will be on the second Phase 3 trial. A win there would solidify Amgen’s standing in the rare disease space and provide a long-awaited clinical solution for a patient population that has long been sidelined by the medical community. For now, the biopharma world awaits the detailed data, knowing that the outcome of this study will likely dictate the standard of care for Sjögren’s for years to come.
